Literature DB >> 32224075

Use of IV Immunoglobulin G in Heparin-Induced Thrombocytopenia Patients Is Not Associated With Increased Rates of Thrombosis: A Population-Based Study.

Binod Dhakal1, Lisa Rein2, Aniko Szabo2, Anand Padmanabhan3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32224075      PMCID： PMC7478227          DOI： 10.1016/j.chest.2020.03.024

Source DB:  PubMed          Journal:  Chest        ISSN： 0012-3692            Impact factor:   9.410


× No keyword cloud information.
  9 in total

1.  Publication bias: what are the challenges and can they be overcome?

Authors:  Ridha Joober; Norbert Schmitz; Lawrence Annable; Patricia Boksa
Journal:  J Psychiatry Neurosci       Date:  2012-05       Impact factor: 6.186

2.  Disease burden, complication rates, and health-care costs of heparin-induced thrombocytopenia in the USA: a population-based study.

Authors:  Binod Dhakal; Lisa Baumann Kreuziger; Lisa Rein; Ariel Kleman; Raphael Fraser; Richard H Aster; Parameswaran Hari; Anand Padmanabhan
Journal:  Lancet Haematol       Date:  2018-05       Impact factor: 18.959

Review 3.  Autoimmune heparin-induced thrombocytopenia and venous limb gangrene after aortic dissection repair: in vitro and in vivo effects of intravenous immunoglobulin.

Authors:  Liane A Arcinas; Rizwan A Manji; Carmen Hrymak; Vi Dao; Jo-Ann I Sheppard; Theodore E Warkentin
Journal:  Transfusion       Date:  2019-03-23       Impact factor: 3.157

4.  IVIg for Treatment of Severe Refractory Heparin-Induced Thrombocytopenia.

Authors:  Anand Padmanabhan; Curtis G Jones; Shannon M Pechauer; Brian R Curtis; Daniel W Bougie; Mehraboon S Irani; Barbara J Bryant; Jack B Alperin; Thomas G Deloughery; Kevin P Mulvey; Binod Dhakal; Renren Wen; Demin Wang; Richard H Aster
Journal:  Chest       Date:  2017-04-17       Impact factor: 9.410

5.  Intravenous Immunoglobulin for Heparin-Induced Thrombocytopenia.

Authors:  Ibrahim F Ibrahim; Lawrence Rice
Journal:  Chest       Date:  2017-10       Impact factor: 9.410

6.  Persistent Heparin-Induced Thrombocytopenia Treated With IVIg.

Authors:  Michelle B Azimov; Evan D Slater
Journal:  Chest       Date:  2017-09       Impact factor: 9.410

Review 7.  High-dose intravenous immunoglobulin for the treatment and prevention of heparin-induced thrombocytopenia: a review.

Authors:  Theodore E Warkentin
Journal:  Expert Rev Hematol       Date:  2019-07-05       Impact factor: 2.929

8.  American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia.

Authors:  Adam Cuker; Gowthami M Arepally; Beng H Chong; Douglas B Cines; Andreas Greinacher; Yves Gruel; Lori A Linkins; Stephen B Rodner; Sixten Selleng; Theodore E Warkentin; Ashleigh Wex; Reem A Mustafa; Rebecca L Morgan; Nancy Santesso
Journal:  Blood Adv       Date:  2018-11-27

Review 9.  Intravenous immune globulin and thromboembolic adverse events: A systematic review and meta-analysis of RCTs.

Authors:  Eric M Ammann; Cole B Haskins; Kelsey M Fillman; Rebecca L Ritter; Xiaomei Gu; Scott K Winiecki; Ryan M Carnahan; James C Torner; Bruce H Fireman; Michael P Jones; Elizabeth A Chrischilles
Journal:  Am J Hematol       Date:  2016-04-24       Impact factor: 10.047
  9 in total
  3 in total

1.  Bleeding is associated with intravenous immunoglobulin and therapeutic plasma exchange use in heparin-induced thrombocytopenia: A propensity matched analysis.

Authors:  Alexandre Soares Ferreira Júnior; Stephen H Boyle; Maragatha Kuchibhatla; Oluwatoyosi A Onwuemene
Journal:  EJHaem       Date:  2021-05-07

Review 2.  Heparin-Induced Thrombocytopenia: A Focus on Thrombosis.

Authors:  Gowthami M Arepally; Anand Padmanabhan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-12-03       Impact factor: 8.311

Review 3.  Heparin-Induced Thrombocytopenia: A Review of New Concepts in Pathogenesis, Diagnosis, and Management.

Authors:  Matteo Marchetti; Maxime G Zermatten; Debora Bertaggia Calderara; Alessandro Aliotta; Lorenzo Alberio
Journal:  J Clin Med       Date:  2021-02-10       Impact factor: 4.241
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.